Purchase Order HT942524P0044
Award Date 2/5/24
Potential Completion Date 9/4/24
Potential Value $250K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Huntsville, AL 35806, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
122
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This federal contract award was made by the Department of the Army Medical Command to Genecapture, Inc., a for-profit startup company, under the Small Business Innovation Research (SBIR) program. The contract, valued at $249,959.25, is for Phase I feasibility research on Genecapture's CAPTURE technology, which enables rapid identification of genetic signatures of pathogens for infectious disease detection and diagnosis. The award has a total small business set-aside designation. Genecapture...
- This is a Small Business Technology Transfer (STTR) Phase I contract awarded by the Defense Threat Reduction Agency (DTRA) to Genecapture, Inc., a for-profit startup company. The $150,523.52 firm-fixed-price contract is for the development of infectious disease diagnostics and differentiation of viral vs. bacterial infections for point-of-care applications. Genecapture specializes in rapid pathogen detection solutions using their patented CAPTURE technology. This contract supports DTRA's efforts...
- This is a $1,271,417.59 Cost Plus Fixed Fee contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Genecapture, Inc., a for-profit startup company. The contract is for a Small Business Technology Transfer (STTR) Phase II effort focused on developing infectious disease diagnostics and differentiation of viral versus bacterial infections for point-of-care applications. The contract was set aside for small businesses. Genecapture specializes in rapid infectious disease...
- Genecapture, Inc. was awarded a definitive contract valued at $1,099,956.91 by the Department of the Army Medical Command to conduct research and development under the Small Business Innovation Research (SBIR) Program Phase II. The contract supports Proposal No. H2-0647 titled "Genecapture's Fieldable Diagnostic Platform for Rapid ID and AST of Wound Pathogens." Research will be conducted in Huntsville, Alabama over a period of performance from September 2021 through January 2024 under...
- Genecapture, Inc. was awarded a $999,752.38 definitive cost-plus-fixed-fee contract by the Defense Threat Reduction Agency to continue research and development efforts initiated under Phase I of the Small Business Innovation Research program. The contract will support the company's work to deliver infectious disease diagnostics and differentiate between viral and bacterial infections for point-of-care applications, advancing the agency's goals of protecting the United States from weapons of mass...
- The Defense Threat Reduction Agency (DTRA) awarded a $4.54 million Phase III Small Business Technology Transfer (STTR) contract to Genecapture, Inc. on November 3, 2023, for the development of infectious disease diagnostics capable of differentiating viral versus bacterial infections for point-of-care applications. The contract, structured as a cost-plus-fixed-fee definitive contract, will be performed in Huntsville, Alabama, with an ultimate completion date of July 31, 2026. This Phase III...
- The Department of the Air Force Materiel Command Research Laboratory awarded a $284,827 Other Transaction Agreement to Genecapture, Inc., a for-profit small business startup, to research and develop a ruggedized and upgraded version of a commercially available pathogen detector that can be deployed in forward environments. This award is not set aside for any specific business type. Genecapture has received prior Small Business Innovation Research (SBIR) Phase II contracts from the Army,...
- The U.S. Defense Health Agency (DHA) awarded a Small Business Technology Transfer (STTR) Phase II contract to Emergingdx Inc., a small business subchapter S corporation based in Lowell, Massachusetts. The $1,299,985.23 Firm Fixed Price contract, which is set aside for total small business, supports the development of a "Multiplexed Diagnostic Platform for Invasive Fungal Infection." This contract builds upon earlier SBIR Phase I exploratory research and aims to advance innovative...
- The Defense Health Agency has awarded a $249,969 Small Business Innovation Research (SBIR) Phase I contract to Emergingdx Inc., a Lowell, Massachusetts-based diagnostic technology company, for the development of an integrated multiplexed low-cost diagnostic platform for rapid microbial identification. This total small business set-aside contract, designated as a purchase order with firm fixed price terms, represents the initial phase of research and development aimed at advancing medical...
- The U.S. Defense Health Agency (DHA) awarded a $249,993.28 Small Business Innovation Research (SBIR) Phase I firm-fixed-price purchase order to Glyphic Biotechnologies, Inc., a minority-owned, small disadvantaged business, for the development of anti-glycan antibodies against multi-drug resistant ESKAPE wound pathogens. The contract has a completion date of November 7, 2024 and was awarded on April 8, 2024. Glyphic Biotechnologies is a biotechnology startup focused on developing...